Curious Encyclopedia | Investment Dilemmas Surrounding Leading Stocks in the Cannabis Industry

What comes to mind when you hear the word 'cannabis'? But do you truly understand cannabis? The Past and Present of Cannabis — 'Half Angel, Half Devil' The cannabis plant contains two natural compounds: tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is a neuroactive substance—and the chief culprit behind cannabis’s classification as a controlled narcotic. In contrast, CBD is non-neuroactive and antagonizes (counteracts) THC, thereby mitigating THC’s effects on the human nervous system; for this reason, CBD is widely used in medical applications. Based on THC content, cannabis is divided into industrial hemp and narcotic (recreational) cannabis. In China, industrial hemp is known as 'Han hemp' and boasts broad applications: hemp fibers are used to produce high-end textiles, while hemp seeds serve as food and animal feed. The editor once spotted a cannabis plant in a remote, rural area—and nearly dialed 110 in alarm… Turns out it was just an ordinary plant… Back home, better snack on some hemp seeds to calm your nerves! Now that we’ve gained a somewhat rudimentary understanding of cannabis, let’s introduce today’s protagonist—the U.S.-listed industrial hemp pioneer Tilray. Company Profile Tilray Inc. is a Canadian pharmaceutical company and cannabis producer headquartered in British Columbia, Canada. It is registered in the United States and operates in Australia, New Zealand, Germany, and other countries, focusing on the sale and development of medical cannabis. Its product portfolio includes dried cannabis flower and cannabis extracts—such as full-spectrum oils, purified oil drops, and capsules. Tilray pioneered the future of global medical cannabis research, cultivation, processing, and distribution. The company owns over 3 million square feet of land dedicated to cannabis cultivation and aims to become a leader in Canada’s adult-use cannabis market. Key Milestones in Its Growth — How a 'Meme Stock' Was Forged July 2018: Tilray listed on the NASDAQ; its stock initially performed modestly. August 2018: A string of positive catalysts triggered explosive share price growth. September 18, 2018: Three major positive developments occurred simultaneously—including a post-market interview with Tilray’s CEO, who hinted at imminent collaborations with alcohol and pharmaceutical companies. September 19, 2018: Tilray’s stock experienced extreme volatility—surging up to 93.57% intraday, gaining $145, and briefly touching the $300 mark. Its market capitalization surpassed $24 billion for the first time—followed by five circuit-breaker-triggered plunges. Wall Street issued warnings, cautioning that cannabis stocks could become the next bubble after cryptocurrencies. As of yesterday, July 2, 2019, Tilray closed at $47.39. Current Legalization Status In 1988, the United Nations explicitly stipulated that cannabis plants containing less than 0.3% THC may be utilized for industrial purposes. In October 2018, Canada legalized recreational cannabis. To date, 34 countries—including Germany, Australia, Israel, and South Korea—have fully legalized medical cannabis; another nine—including the UK, France, and New Zealand—have partially legalized certain medical cannabis products under strict regulation. Overview of the Industrial Hemp Industry After a bumpy, three-steps-forward-two-steps-back path toward legalization, industrial hemp is currently used primarily in fiber-based products and medical applications.

GPLP Investment & Financing News: Sino-American RuiKang Raises Nearly RMB 200 Million; YouDi Secures Over RMB 100 Million

YouDi Completes Series B Financing Exceeding RMB 100 Million YouDi, a supply-chain platform for recycled automotive parts, announced completion of a Series B financing round exceeding RMB 100 million. This round was led by YUE Capital, with follow-on investment from NIO Capital. According to reports, the proceeds will primarily fund upgrades to remanufacturing technologies, continued expansion of domestic operations, and entry into overseas markets. Hanfeng Technology Completes Over RMB 100 Million Series B Financing Recently, IoT company Hanfeng Technology announced completion of a Series B financing round exceeding RMB 100 million, led by Walden International, with Haier Capital joining as a new investor. Previously, Hanfeng Technology had secured Series A funding from Jingfeng Mingyuan and Baidu. Sino-American RuiKang Raises Nearly RMB 200 Million in Series A+ Financing Sino-American RuiKang—a developer of small activating RNA (saRNA) therapeutics—recently completed a Series A+ financing round nearing RMB 200 million. The round was led by SDIC Venture Capital, with participation from multinational pharmaceutical company Eisai (Japan), Lingcheng Venture Capital, Zhongxin Capital, and Xianghe Chengdao. Miraik Completes Nearly RMB 100 Million Series A Financing Miraik—a provider of home fitness equipment—has completed a Series A financing round nearing RMB 100 million. Investors include Tootoo Is Dao Investment Fund and Hougu Investment (financial advisor).

Oil-Dri Corp of America Stock Hits All-Time High of $99.16

Jun 24, 2026

Oil-Dri Corp of America shares reached an all-time high of $99.16 following robust Q3 fiscal 2026 earnings with net sales up 9%. The company also raised its dividend for the second time this year.

Investing.com

2026-03-25

Oil Dri declares $0.205 dividend

2026-03-25

Oil-Dri Q1 Earnings Decline Year-Over-Year Amid Tough Comparison Pressures

2026-04-03

Oil-Dri Updates Deferred Compensation Plan and Restricted Stock Agreements

2026-04-03

Oil-Dri Corporation of America Insiders Dispose Stock Amid Bearish Signals

2026-04-04

Oil-Dri Corporation Share Price Crosses Above 200-Day Moving Average